T he use of antipsychotic medications in pediatric patients has increased exponentiallyover the past decade.' This is likely due, in part, to increased recognition and diagnosis of psychiatricdisorders in younger populations. Currently, risperidone, aripiprazole, and olanzapine are the second-generation antipsychotics (SGAs) approved for use by the Food and Drug Administration (FDA) in children and adolescents with irritability associated with autism, bipolar mania, or schizophrenia. However,off-label use of SGAs, including c1ozapine, paliperidone,quetiapine, and ziprasidone, is commonin pediatric patients withthesediagnoses? Firstgeneration antipsychotics (FGAs) withindications for children and adolescents include haloperidol, pimozide, and thioridazine. Patients with disruptive behavioral disorders, mental retardation, tic disorders, as well as numerousother childhood psychiatric conditions are also prescribed antipsychotic agents in selected cases.' Long-term treatment with FGAsis associated withmovement disorders such as tardive dyskinesia and extrapyramidal symptoms (EPS).4This is well documented in both adult and pediatric psychiatric patients. Tardivedyskinesia is also a significant risk in children prescribed FGAsin long-term therapy.'
A numberof studies investigating the safetyand utilization of SGAs in children and adolescents have been conducted. The incidence of adverse effects,particularly EPS, in patients with schizophrenia appears to be higher in adolescents compared with adults," Similarly,the results of a pilot study of the use of antipsychotics in psychotic youth indicated more prevalent and severe EPS in pediatric patients compared with adults,"
EPSarethought to be related to dose-dependent dopamine type-2 (DJ receptor antagonism in the nigrostriatal dopamine pathway. Significant D, antagonism disinhibits acetylcholine releasefrom cholinergic interneurons, which results in increased motor activity. There is a correlationbetween the numberof these receptorsand age, which may predispose younger patients to antipsychotic-associated EPS.6,7 While all currently available antipsychotics antagonize D, receptors, FGAs bindtightly and generally dissociate more slowly than theirsecond-generation counterparts. This is hypothesized to be one mechanism underlying increased EPS liability fromolder agents," In addition to this theory, SGAs,unlike FGAs, antagonize serotonin-2A receptors. Antagonismof these receptorsresults in an increased release of dopaminein the nigrostriatal pathway, which is hypothesized to counteractthe negative effectsof D, blockade in this area of the brain? Clinical observationssuggest that children and adolescentsmay be moresensitive to EPS,evenfromsomeSGAs, and often require adjunctive therapy with anticholinergic agents. Centrally acting anticholinergic medications areused to treat EPS. Commonly used medications include benztropine, diphenhydramine, and trihexyphenidyI. Whilethese agents may alleviate EPS in many pediatric and adult patients,they are also associated with cognitiveimpairment, which is an issue of greatconcern in thispatient population," Pediatric patients with psychiatric disorders may have difficulty performing in school due to the disorders themselves; cognitive impairment induced by anticholinergic agents used to treat EPS resulting from antipsychotic use is a compounding factor that may worsen this issue. Anticholinergic agents have a dose-dependent negative effect on cognition,"These agentsimpairverballeaining of new material and declarative memory,although in the clinical setting, the potential adverse consequences of anticholinergic treatments oftenare overlooked.
The rationale for this study is that clinical observations suggestthat anticholinergic medications are commonly utilizedin pediatric patients prescribed both FGAsand SGAs, despite the theoretical decrease in incidence of EPS with SGAs. However,the scope of anticholinergic use and differences across antipsychotic classesand individual agents has not been extensively studied.In this study, we characterizedthe proportion of pediatric patients at a major Midwest academic medical centerwho weretakingan antipsychotic and received an anticholinergic agent for the man-agement of EPS;we compared the usage of anticholinergics across children and adolescents receiving aripiprazole, risperidone, and quetiapine, known to be the 3 most commonlyprescribed SGAs for youngerpatients at this center.
Methods
This was a retrospective,medical record evaluation of patients seen at a majorMidwest academic medical center. The study was approved by the local institutional review board. Our primaryobjective was to determine the proportionof patients 5-18 years of age who received anticholinergic therapy during the initial stages of antipsychotic treatment.The secondary objective was to compare anticholinergic utilization across patients receiving aripiprazole, risperidone, and quetiapine. These3 agents are known from previous drugutilization analyses (data notpresented here) to be the mostcommonly prescribed SGAsat the medical center described here. Additionally, variables such as demographic information, psychiatric diagnoses, antipsychotic doses, and prescribing of other medications (psychotropic and nonpsychotropic) were evaluated with regard to anticholinergic utilization. Children and adolescents 5-18 years of age were included for study if theyfilled a prescription for any antipsychotic agent between January 1, 2005, and September 1,2008, at one of the institutional pharmacies. The database for 5 outpatient pharmacies affiliated with the hospital wasaccessed anda search wasperformed to identify prescription fillhistory of patients meeting thesecriteria. Patients whoreceived at least2 prescriptions of an antipsychotic, spanning 60 days, wereselected for inclusion. Use of an antipsychotic for a minimum of 2 consecutive refills, perthe institution's pharmacy database, wascorroborated withdocumentation in theelectronic medical record of utilization for a period spanning a minimum of 60 daysduring the sametime period. For patients who received more than one separate therapeutic course of an antipsychotic during the study period, onlydata from the first medication course wereincluded in these analyses. Exclusion criteria consisted of age >18 years,as wellas presence of a non-antipsychotic medication (such as metoclopramide or prochlorperazine) or neurologic disorder known to elicitEPS.Weexcluded patients who had documented utilization of an antipsychotic agent in the previous 60 days as notedby eitherprescription recordsor electronic medical records. Patients for whom there was not enough information availablein the medical records were alsoexcluded.
Data collected included demographic characteristics (age at time of antipsychotic initiation,sex, race/ethnicity, height,and weight), medical and psychiatric diagnoses, antipsychotic therapy, anticholinergic therapy, medication doses and schedules, length of antipsychotic and anticholinergic therapies, and documentation of EPS, Antipsychoticclass wasdefinedas first-generation, second-genera-Anticholinergics in Children and Adolescents After Initiation ofAntipsychotic Therapy tion, or polypharmacy (the simultaneous use of~2 scheduled antipsychotics). While patients and antipsychotic agents used were identified through the pharmacy prescription database, additional medication information (ie, use of medications other than antipsychotic agents) was derived from the electronic medical record. EPS were definedeither as documentation of EPS in the medicalrecord or documentation of symptoms consistent with akathisia (eg, inner restlessness or restlessness qualified as akathisia by the treating clinician),pseudoparkinsonism (eg, tremor, cogwheel rigidity, akinesia), or dystonia. One instance of "EPS-associated agitation" and another describing "EPS" but withoutfurtherdetails were both considered documented EPS for the purposes of the data reported here. Patient diagnoses were documented in the medical record by the treating physician. Diagnoses consistent with categories outlinedin the Diagnostic and Statistical Manualof Mental Disorders, (4th ed., text revision, 2000) were categorized as "Axis I Psychiatric Diagnoses."
In additionto antipsychotic agents,prescriptions for other psychotropic medications, as documented in the electronic medical record, were identified.These medications were classified into 4 categories: mood stabilizers,antidepressants, stimulants, and a-agonists.Utilization of theseadditional psychotropic medicationswas compared between patients prescribed an anticholinergic agent30 days afterantipsychotic initiation and those who were not prescribedan anticholinergic agent. Mood stabilizer medications included lithium, carbamazepine, divalproex sodium, lamotrigine, and oxcarbazepine. Antidepressants prescribed in this patient population included selective serotonin-reuptake inhibitors, tricyclic antidepressants, serotonin! norepinephrine-reuptake inhibitors, mirtazapine, and atomoxetine. Atomoxetine, indicatedfor the treatment of attention deficit hyperactivity disorder (ADHD),was categorized as an antidepressant because of mechanistic similarities (norepinephrine-reuptake inhibition) and to separate it from the stimulantcategory.Stimulants included amphetaminederivativessuch as dextroamphetamineand amphetaminesalts, as well as methylphenidate products. o-Agonistsprescribed included clonidine and guanfacine. Clinicaldata were reliably available at the time of antipsychotic initiation and at l-monthfollow-up appointments. Subsequentclinical visits were inconsistent. Therefore,the analyses presented hererepresent utilization overthe first30 daysof therapy.
STATISTICAL ANALYSIS
Summary statisticsfor demographic characteristics,antipsychotic use, anticholinergic use, indication,diagnoses, and relative doses were tabulatedfor the study sample as a whole. Chlorpromazineequivalents were calculated using previouslydescribedmethods by Kane" and Woods'! in an effort to standardize antipsychoticdoses. Recognizing the limitations of these conversions, we reserved the use of chlorpromazine equivalents for secondaryanalysesto gain insight on dose as a potential predictor of anticholinergic utilization in patientsreceiving any antipsychotic.
The Sapiro-Wilk testwas usedto determine thatage, total number of diagnoses,numberof psychiatric diagnoses,antipsychotic doses(measured in chlorpromazine equivalents), total number of scheduled medications at antipsychotic initiation, and total number of psychotropic medications at antipsychotic initiation all significantly deviated from a normal distribution (p < 0.05).The Mann-Whitney U testwas thereforeusedto compare age,total number of diagnoses, number of psychiatric diagnoses,antipsychotic doses (measuredin chlorpromazine equivalents), total numberof scheduled medicationsat antipsychotic initiation, and totalnumberof psychotropic medications among patients who were on an anticholinergic 30 days from antipsychotic initiation and those who werenot.Pearson's X 2 testwas usedto compare the proportion of males and females among patients who wereprescribed an anticholinergic agent30 days after initiation of an antipsychotic and those who were not. Pearson'sX 2 test was also used to compareuse of an anticholinergic 30 days after initiation of an antipsychotic betweenpatients using FGAs, SGAs,and polypharmacy. We alsocompared anticholinergic utilization acrossSGAs only. Basedon priordrug utilization analyses of antipsychotic utilization at the institution (datanot shown),the 3 mostcommonly prescribed SGAs at this institution were risperidone,quetiapine,and aripiprazole. Pearson's X 2 test was used to determine whetheranticholinergic utilization significantly differed across these3 agents.
Univariate and multiple logistic regression analyses were performedto assessodds ratiosof potential predictors of anticholinergic utilizationafter 30 days. The dependent variable was anticholinergic order/prescription after 30 days. Independent variables includedsex (male vs female), age, total number of diagnoses, number of psychiatric diagnoses, antipsychotic class, starting antipsychotic dose, and dose of antipsychotic after 30 days. A multivariate analysisfollowed, which included variables with potentially significant evidence for association at the p < 0.10 level identified in univariateanalyses. The final model was chosen according to a backward elimination model selection technique, which resulted in the inclusion of 3 variables. Model fit assessmentwas conducted with the Hosmer and Lemeshowgoodnessof fit test.
All statistical analyses were conducted using SAS JMP version7 (SAS Institute, Cary,NC) and SPSS version 15.0 (SPSS Inc., Chicago, IL).
Results
A total of 235 antipsychotic treatment courses were identified, representing 195 patients. Of these, 179 treatment courses or 152patients were included in the follow-
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ing analyses. For patients with multiple antipsychotic courses, only the first course was includedfor assessment (n = 152). The mostcommon reasonfor exclusion of treatment courses was lack of information in the medical records (n =19),followed by absence of records indicating use of antipsychotic for at least 2 months(n = 9) and turning 19 years of age during the follow-up time frame (n = 7). Other reasons for exclusion included prescription fill dates prior to or beyond the dates of interest (n = 4), as well as EPS potentially associated with utilization of a nonantipsychotic medication, as documented in the electronic medical record (n = 3), and misidentification resulting in records of prescriptions under 2 different names (n =1).
Demographic characteristics are summarized in Table I . Psychiatric diagnoses (see Figure I ) included bipolardisorder,majordepressive disorder, schizophrenia, posttraumatic stress disorder, ADHD, developmental disorders (eg, autism, mental retardation) and other disorders (eg, intermittentexplosivedisorder,oppositional defiant disorder). The mostcommonpsychiatric diagnosis was bipolar disorder (n = 66). Patients had a median of 2 (range 1-3) psychiatric diagnoses documented in the medical records.
The most commonly prescribed antipsychotics in this study wererisperidone (27%, n =4l),quetiapine (27%, n = 41), and aripiprazole (16%,n =24). OtherSGAsprescribed included ziprasidone (10%,n = 15), olanzapine (5%,n = 8), and clozapine(2%, n =3). FGAs (fluphenazine, chlorpromazine, haloperidol) were prescribed in 6 (4%)patients. Additionally, 14patients were prescribed multiple antipsychotics concomitantly at the initiation of therapy (9%).Meandaily doses ± SD at thefirst identified timepointfor use in theclinical recordaveraged 2 ± 1.8 mg/day for risperidone, 425 ± 293 mg/day for quetiapine, and 14± 85 mg/day for aripiprazole. Mean daily doses of other antipsychotics at baseline were: ziprasidone 110 ± 43.8 mg/day, olanzapine 15 ± 12.5 mg/day, clozapine 150 ± 60.5 rug/day, fluphenazine 25 mg/day, chlorpromazine 300 mg/day, and haloperidol 175 ± 10.4mg/day. The total numberof medications prescribed for patients in this study ranged from 1 to II , with a median of approximately 3.5 medications per subject. These patients received a median of 2 (range 1-4) psychotropic medications at the initiationof antipsychotic therapy. Additional non-antipsychotic psychotropic medications, such as stimulants, mood stabilizers,antidepressants, and a-agonists, are summarized in Figure 2 . At the documented time of antipsychotic initiation, mood stabilizers were the most commonlyprescribed concomitantmedications, followed by antidepressants, stimulants, and a-agonists.
Concomitant use of centrally acting anticholinergic medications with an antipsychotic at any time was identified in 32 patients (21 %). Utilization of non-centrally acting anticholinergic agents such as oxybutyninwas identified,but thesedrugs were not included for thisanalysis due to their different indications. Initiation of the anticholinergic occurred concurrently with antipsychotic initiation in 20 (625%) patients. At 30 days from antipsychotic initiation, a total of 28 of these 32 patients (875%) were prescribed anticholinergic medications. Patients were initiated on an anticholinergic agent within 30 days of antipsychotic initiation usually afterthe occurrence ofEPS as documented in the medical record, although time to occurrence of EPS after initiation of an antipsychotic and/oranticholinergic utilization was not collected. Benztropine was the most frequently prescribed anticholinergic (n = 32); 1 subject also received diphenhydramine, whichwas documented as being used for EPS. EPS were documented in the medical record of 8% of all patientsand 12 of 32 patientsusing an anticholinergic agent(seeTable 2).
Prescribing of anticholinergic drugs was mostcommonly observed in patients diagnosed with schizophrenia and/or ADHD (see Figure 3 ). Anticholinergic medication utilization was also analyzed according to specific agents and antipsychotic class (FGA vs SGA vs polypharmacy). Overall, an anticholinergic agent prescribed at 30 days from antipsychotic initiation was most commonin patients who were prescribed an FGA (4 of6 pts., 67%).Of the 14 patients using multiple antipsychotics, 9 (64%) were prescribed an anticholinergic at 30 days after initiationof an antipsychotic. Of the remaining 132patients prescribed an SGA, 17 were using an anticholinergic at 30 days (13%; p < 0.001 for comparison across FGA, SGA, and polypharmacy) Among the 3 most commonly prescribedSGAs in this study,anticholinergic utilization after 1 monthdiffered significantly (p = 0.03) and was most commonly documented in patients using risperidone (Figure 4 ). Anticholinergic utilization was documented in 2 patientsusing aripiprazole at the start of therapy,but these were discontinuedpriorto the 30-day time point.
Anticholinergic users and non-users were examined for differences in age, sex, antipsychotic dose, total number of medications, number of psychiatric diagnoses, and total number of diagnoses. Statistically significant differences were identified between anticholinergic users and non-users in sex, antipsychotic dose, total number of medications, and number of psychiatric diagnoses (see Table 3 ).
Univariate logistic regression analyses, with anticholinergic utilization at 1 month from antipsychotic initiation as the dependent variable, were performed using individual demographic and clinical variables as possible predictors (Table 4 ). Univariate odds ratios were calculated indicating a potentially significant association between the following variables and anticholinergic utilization: male sex, total number of Axis I diagnoses, antipsychotic class, starting Anticholinergic drugswere prescribed in 2 patientsat initiation of aripiprazole; thesedrugs werediscontinued priorto the 30·day follow-up. p =0.03 chotic class alone was found to be significantly associated with an increased likelihood of a patient receiving a prescription for an anticholinergic within 30 days of antipsychoticinitiation (OR =18.98; 95% CI 4.74 to 75.95).
Discussion
The primary finding of this study is that prescriptions for anticholinergics were documented in 21% of children and adolescents receiving antipsychotics for various psychiatric disorders. Utilization was approximately 13% in patients prescribed only a SGA and was most common in patients prescribed risperidone.
Frequency of anticholinergic prescribingexceededthe documentedincidenceofEPS of8% in this study sample. Approximately 39% (12/32)of patientsreceiving an anti-cholinergic agent had EPS documented in the medical record. Anticholinergic medications wereoften initiated at thesametime as initiation of an antipsychotic, indicating that theymayhavebeenprescribed prophylactically. Riskfactors fordystonic reactions, which are mostlikely to occurearlyin therapy, include FGAs, higher antipsychotic doses, and male sex." These variables were individually identified as being significantly associated withanticholinergic use in thissample,which supports our hypothesis thatanticholinergics were prescribed in a prophylactic manner. Of the3 mostcommonly prescribed SGAs, risperidone was associated with the greatest utilization of anticholinergics. However, for risperidone-treated patients, 8 of 9 receiving an anticholinergic had therapynoted after antipsychotic initiation,indicating that thiswas notprophylactic but rather for antipsychotic-induced EPS. Interestingly, all patientsreceiving an anticholinergic along withquetiapine had thiscombination noted at baseline andalsoat follow-up. While quetiapine doesnothaveappreciable affinity for mus-carinicM. receptors, its metabolite, norquetiapine, has moderateaffinity for these receptors, which is thought to account for the extremely low rates of EPS observed clinicallywith this drug. Thus, the reasonsfor concomitant use of an anticholinergic with quetiapine at treatment initiation in these patientsare unclear.1\\10 patients were prescribedan anticholinergic at the initiation of aripiprazole, withno anticholinergic utilization notedat follow-up. This is consistent with clinical observations that aripiprazole may occasionally be associated withakathisia during the initial stages of therapy, which maybe targeted prophylactically. After controlling for other variables associated with anticholinergic use, antipsychotic class was the primary predictor of use. Our Antipsychotic daily dose at lnitiatlon d 0.00110 0.000527 0.037 1.001 1.000 to 1.00 2
Antipsychotic daily dose at 1 month" 0.00100 0.000489 0.04 1 1.001 1.000 to 1.002 "Total number 01medical and psychiatric diagnoses recorded in the medical record in the most recent primary care and psychiatry notes 01trealing physiclans.
bChart·documented psychiatric diagnoses categorized in the Diagnosticand Statistical Manual of Mental Disorders, 4th ed., text revision.
"Firs t-generation antipsychotic or polypharmacy vs second-generation antipsychot ic. din chlorpromazine equivalents.
theannals .com
The AnnalsofPharmacotherapy • 2010July/August. Volume 44 • 1177 findings suggestthat anticholinergics were prescribed prophylactically with FGAs. Predictors other than antipsychotic class have been investigated. Antipsychotic dose, for example, has been suggested as a predictor of anticholinergic use. In a review by Pierre, the likelihood of EPS was determined to increase when higher doses of SGAs were administered, due to a greater blockade of O 2 receptors."In adults,risperidone has a dose-response relationship with movementdisorders." However,the results presented in a case seriesby Kumraet al. are conflicting"; the rate of antipsychotic-related dyskinesia was assessed in 34 children and adolescents who were diagnosed with schizophrenia and receivedclozapine,olanzapine,risperidone,or haloperidol (haloperidol in combination withbenztropine). Comparing patients withand without dyskinesia, no significant difference was found in sex, age, and other variables, including admission doses of antipsychotics. These results suggest thattheincidence of EPS andthe needfor anticholinergic medications may not be linked to antipsychotic dosealone; further evidence is necessary to validate the predictive capability of antipsychotic dose as wellas otherfactorssuchas sex and number of psychiatric diagnoses. In our study, antipsychotic dosewasfound to differ significantly between patients who were prescribed an anticholinergic and those who were not; however, due to the wide variation in dosing,a set dose (in terms of chlorpromazine equivalents) above which patients were more likely to require an anticholinergic could notbe defined.
Our study had limitations that warrant consideration when interpreting the results.The external validityof-this sample is unknown due to the relatively modest sample size, demographic distribution, and retrospective natureof data collectionfrom a single center.Time points for clinical follow-up past 30 days were inconsistent. Thus, while 60 days of documented antipsychotic use was an inclusion criterion, the clinical follow-up for many patients was highly variable,which led us to focus our analyses on the initial 30 days of treatment.Long-term utilization of anticholinergics was therefore not analyzed in this study.
Several of the patients initially identified had transferred to this institution from outside facilities, from which records were not available.This made the psychiatric history and priorantipsychotic and anticholinergic medication history difficult to discern/ascertain and also resulted in the exclusionof a numberof patientsfrom our potential study sample. In our efforts to obtain a best estimate of newly initiated antipsychotics, we excluded patients with documentedantipsychotic use in the previous 60 days.This was done through an assessment of information in the prescription databaseas well as the electronic medical record.Despite theseefforts, there were some patientsidentified with doses at drug initiation that were higher than recommended. This couldbe due to initial therapy that was started during a brief period prior to referral and not documented for some patients. However, due to the aforementioned efforts to'identify patients receiving antipsychotics in the previous 60 days, these data are still representative of the initial stagesof therapy.
In addition,there were a large number of prescribers in this study (n =75). Due to the number of prescribers, we were not able to adequately assess whether an individual physician'sprescribing behavioror preference is a predictor of anticholinergic use. However, the high number of prescribers and the extensive heterogeneity of the diagnoses limit the likelihood that our results were skewed by individual prescribers or diagnoses. Another important consideration aboutour sampleis the method of identification. Because we used the institution's pharmacy database, patients receiving their medications through outside pharmacies were not included. We do not know whetherthere are variables that differbetween those populations thatmay haveinfluenced the results here. Finally,one of the reasonsfor conducting this study is that anticholinergic use may be associated with impaired scholastic performance. This hypothesis is based on prior studiesinvestigating the relationship between anticholinergic activity and cognition.We did not assess the relationship between anticholinergic use and scholastic performance in this sample,which should bethe topic of future investigations.
In this study sample of children and adolescents using antipsychotic agents, concomitant utilization of an anticholinergic agent was documented in 21% of patients at some point over the course of the first 30 days of therapy. To our knowledge, this is the first investigation to specifically study anticholinergic utilization during the initial stages of antipsychotic treatment in a real-world clinical population. Antipsychotic use was observed in both indicated and off-label diagnoses, and there was a discordance betweenthe utilization of anticholinergic agentsand documented indicationsfor their use. Antipsychotic class was the variable associated with the greatestlikelihood of anticholinergic use, and there were differences across the 3 most commonly prescribed agents in the SGA class (risperidone, aripiprazole, and quetiapine). This collectively indicates that youngerpatients may be sensitive to EPS, even from SGAs. The overall medication burden, particularly psychotropics, was high in our studysample. Furthermore, with the exception of increased antidepressant utilization after 30 days, total psychotropic utilization did not change after antipsychotic initiation. Additional larger scalestudies are needed to determine unequivocally the relationships between these variables and the risk for anticholinergic use. The clinical realities and challenges of psychotropic use in youngerpatients,however, should not deter further study of this population. At this time, anticholinergic therapy may be required for treatment of antipsychotic-induced EPS in both adult and pediatric patients. Although prophylactic use of anticholinergics may EXTRACTO TRASFONDO: Se consideraque los antipsic6ticos de segundageneraci6n (ASG)tienenmenosprobabilidades deinducirsfntomas extrapiramidales (SEP) que los antipsic6ticos de primera generaci6n(APG). Las observaciones clfnicassugieren que los pacientes mas j6venes pueden ser mas sensibles a los SEP asociados a ASG que los adultos y que puedenrequerir tratarnientocon agentes anticolinergicos.
OBJETIVO: EI objetivo principalde este estudio fue determinar la propor-ci6n de pacientesentre 5 y 18 aiios que recibfanterapia anticolinergica durante las fases inicialesdel tratamientoantipsic6tico.Un objetivo secundariofue comparar el uso de anticolinergicos en pacientesbajo tratarnientocon aripiprazol,risperidona,y quetiapina,los ASG prescritos con mas frecuenciaen la instituci6nacadernicade estudio.
MtroDOS: Se identificaron pacientes entre5 y 18aiiosque iniciaron un ciciode tratarnientoantipsic6ticoentre el I de enero de 2005 y el I de septiembre de 2008en una revisi6nretrospectiva delos registros medicos y de prescripci6n. A partirde los datosdelos registros medicos se obtuvieron las caracterfsticas demograficas, eI uso deantipsic6ticos y anticolinergicos, las indicaciones, los diagn6sticos, y los medicamentos concomitantes. Solo se analiz6el primercicloterapeutico con eI antipsic6tico identificado. Se evalu6el usode anticolinergicos al iniciodel tratarniento antipsic6tico y a los 30dfas . RESULTADOS: Se identificaronun total de 235 ciclos de tratamientoanti-psic6ticos. Deestos, 152pacientes cumplfan nuestros criterios de inclusi6n. Se identific6el uso de anticolinergicos en cualquier momento durante los primeros 30 dfas de tratamientoen 32 pacientes(21%), rnientrasque los SEP se documentaron en 12pacientes (7.8%).Los APG 0 la polifarrnacia (uso simultaneode O!: I antipsic6ticoprescrito)en comparaci6ncon los ASG (OR = 18.98; IC 95% 4.74 Y75.95)fue la caracteristica principal asociada de forma significativacon el uso de anticolinergicos a los 30 dias trasel iniciodel tratarniento. Deentre losASG mas comunes,los anticolinergicos se prescribieron con mas frecuencia con risperidona (p =0.03). CONCLUSIONFS: La prescripci6nde anticolinergicos supero la incidencia de SPE documentadaen los registros medicos (21% vs 7.8%) y difirio en funci6ndel tratamientoindividualy la clase antipsic6tica. EI uso de APG 0 polifarmaciafue un indicadorclave del uso de anticolinergicos, premieregeneration: Desobservations c1iniques suggerent que les patientsplusjeunes seraient plus susceptibles de developper des SEP suite11 la prised'antipsychotiques atypiques que les adulteset requierent done un traitement avec des agentsanticholinergiques.
OBJECfIF: L'objectifprimaire de cetteetudeest de determiner la proportion de patients de 5 ans 11 18 ans qui ont recu un traitement anticholinergique lorsdes premieres semaines de traitement avec un antipsychotique. Un objectifsecondaire etait de comparerl'utilisation des anticholinergiques chez les patientsrecevant de l'aripiprazole, de la risperidone ou de la quetiapine, les agentsantipsychotiques atypiques les plusprescrits dans I'institution etudiee. On a observeune utilisation des anticholinergiques a n'importe lequelmomentdurantles 30 premiers jours de traitement chez 32 patients(21%) alorsque des SEP ont ete documentes chez 12 patients (7.8%).Les antipsychotiques de premiere generation ou la polypharmacie (utilisation simultanee de plus d'un antipsychotique) par rapportaux antipsychotiques atypiques (rapportde cote de 18.98; Ie 95% 4.74 11 75.95)etaientles caracteristiques primaires significatives lieesal'utilisation des anticholinergiques dans les 30 jours du debutde traitement par un antipsychotique. Parmi les troisantipsychotiques les pluspreserits.Ies anticholinergiques etaientIe plus souvent preserits avec la risperidone (p = 0.03).
CONCLUSIONS: La prescription d'agents anticholinergiques etait superieure 11 l'incidencedes symptomes extrapyramidaux documentes dans les dossiers medicaux (21% vs 7.8%)et differait selonles medicaments pris par chaqueindividu et la classed'antipsychotique. L'utilisation des agentsantipsychotiques de premiere generation ou la polypharmacie (plusd'un antipsychotique) sont les meilleurs predicteurs de l'utilisation des agentsanticholinergiques.
